Myriad Genetics

Health biotech clinical research genetics hospitals medical diagnostics oncology

Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.

Revenue(FY, 2016)

$753.8 M

Market capitalization(2018-04-25)

$2 B

Type

Public

Salt Lake City, US

Founded

1991

Size (employees)

2,400 (est)

Website

myriad.com

Myriad Genetics was founded in 1991 and is headquartered in Salt Lake City, US

Report incorrect company information

Myriad Genetics Office Locations

Myriad Genetics has offices in Schiphol, London, Issy-les-Moulineaux, El Soto de la Moraleja and in 7 other locations

Salt Lake City, US (HQ)

Myriad Genetics, Inc. 320 Wakara Way

Austin, US

3300 Duval Rd

South San Francisco, US

341 Oyster Point Blvd

Issy-les-Moulineaux, FR

13 Rue Camille Desmoulins

Martinsried, DE

Bunsenstrasse 7

Planegg, DE

Fraunhoferstrasse 18a

Show all (11)

Report incorrect company information

Myriad Genetics Financials and Metrics

Myriad Genetics Financials

Myriad Genetics's revenue was reported to be $753.80 m in FY, 2016 which is a 4.2% increase from the previous period.

Summary

USD
Revenue (Q3, 2017)	196.9 m
Net income (Q3, 2017)	4.2 m
EBIT (Q3, 2017)	12.9 m
Market capitalization (25-Apr-2018)	2 b
Cash (31-Mar-2017)	123.8 m
EV	2.1 b

Myriad Genetics's current market capitalization is $2 b.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	778.2 m	723.1 m	753.8 m
Revenue growth, %		(7%)	4%
EBIT	274.4 m	134.2 m	166.8 m
EBIT margin, %	35%	19%	22%

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue	202.5 m	204.1 m	182.9 m	168.8 m	184.4 m	180 m	183.5 m	193.3 m	190.5 m	177.5 m	196.5 m	196.9 m
Operating expense total	119.6 m	121.1 m	127.6 m	142.9 m	148.1 m	144.2 m	140.2 m	148.1 m	147.9 m	171.3 m	183.3 m	184 m
EBIT	82.9 m	83 m	55.3 m	25.9 m	36.3 m	35.7 m	43.3 m	45.2 m	42.6 m	6.2 m	13.2 m	12.9 m
EBIT margin, %	41%	41%	30%	15%	20%	20%	24%	23%	22%	3%	7%	7%

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	64.8 m	64.1 m	68.5 m
Accounts Receivable	3.8 m	1.9 m	3.3 m
Inventories	23.9 m	25.1 m	38.3 m
Current Assets	322.4 m	283.6 m	314.5 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	85 m	71.6 m	85.8 m	69.8 m	59.7 m	55.2 m	87.4 m	134.7 m	120.5 m	86.9 m	108.1 m	123.8 m
Accounts Receivable	1.8 m	3.5 m	3.2 m	11.2 m	5.3 m	3 m	1.6 m	5.1 m	2.9 m	4.6 m	3.9 m	4.4 m
Inventories			18.9 m	24.8 m	20.2 m	29.4 m	34.3 m	29.1 m	25.3 m	53.9 m	51.3 m	47.4 m
Current Assets	458.7 m	454.5 m	338.2 m	335.4 m	320.1 m	282.4 m	307.3 m	375.5 m	372.4 m	322.9 m	341.6 m	348.3 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	176.2 m	80.2 m	125.3 m
Depreciation and Amortization	13.8 m	25 m	26.7 m
Inventories	(16 m)	(800 k)	(15 m)
Accounts Payable	(1.5 m)	(3.1 m)	(3.1 m)

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Net Income	55.5 m	50.4 m	36.8 m	16 m	24 m	21.5 m	26.6 m	30.3 m	32.6 m	(1.2 m)	5.9 m	4.2 m
Inventories				24.8 m	20.2 m	29.4 m	34.3 m	29.1 m	25.3 m	53.9 m	51.3 m	47.4 m
Accounts Payable				25.7 m	16.8 m	18 m	15.8 m	16.5 m	13.8 m	19.9 m	22.9 m	26.8 m